Immune Pharmaceuticals Inc. Sees Share Volume Rise 130 Times Higher Than Three Month Average

Publishing & Media

Share Tweet

Immune Pharmaceuticals Inc. Sees Share Volume Rise 130 Times Higher Than Three Month Average

Immune Pharmaceuticals Inc. (OTCQX: IMNP) saw its share volume skyrocket on June 19th with 1,615,846 shares exchanging hands, more than 130 times its three month daily average volume of 12,387 shares.

With no recent news on the company, one could only speculate why the uptick in volume occurred, but here is what is known about the company:

Immune Pharmaceuticals Inc. applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company's lead product candidate, Bertilimumab, is in clinical development for moderate to severe ulcerative colitis and Crohn's Disease as well as bullous pemphigoid, an orphan auto-immune dermatological condition, Immune licensed worldwide rights for systemic indications of bertilimumab from iCo Therapeutics (OTCQX: ICOTF) in June 2011, while iCo retained rights to all ophthalmic indications. iCo originally licensed the exclusive world-wide rights to bertilimumab in 2006 from MedImmune, the Global Research and Development Arm of AstraZeneca. Immune's pipeline also includes NanomAbs(R), antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics., Crolibulin, a small molecule in Phase II in collaboration with the National Cancer Institute and Amiket(TM), a Neuropathic Pain drug candidate ready for Phase III. Amiket has received Orphan Drug Designation for Post Herpetic Neuralgia.

IMNP closed the day at $2.70. is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:

Titan Pharmaceuticals Receives Notice of Allowance From US Patent Office

Titan Pharmaceuticals, Inc. (OTCQB: TTNP) saw its share volume soar on June 19th with 946,179 shares exchanging hands, more than seven times its three month daily average volume of 127,267 shares.

Earlier this month, Titan Pharmaceuticals, Inc., a specialty pharmaceutical company developing proprietary therapeutics for the treatment of opioid dependence and other serious medical disorders, announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering the sustained release of dopamine agonists utilizing ProNeura(tm), Titan's proprietary long-term drug delivery technology. The patent, titled "Implantable Polymeric Device for Sustained Release of a Dopamine Agonist," provides intellectual property protection for the company's development program of ProNeura for Parkinson's disease and carries a patent term to at least 2024. Similar patents have been issued in Europe, Australia, Canada, Japan, Korea, Mexico, New Zealand, South Africa and Hong Kong, and patent applications are pending in Israel, India and China.

"This patent allowance is a significant milestone for Titan, as we advance our ProNeura for Parkinson's development program," said Titan President Sunil Bhonsle. "The ability to maintain stable, non-fluctuating, around-the-clock blood levels of dopamine agonists has the potential to improve the health of the estimated seven to 10 million people who are suffering from Parkinson's disease worldwide today, and we are pleased to receive this IP protection."

TTNP closed the day at $.845, 12.94% more than its previous close of $.7482. is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:

International Stem Cell Announces Acute Toxicity Study

International Stem Cell Corp. (OTCQB: ISCO) saw its share volume surge on June 19th with 4,736,107 shares exchanging hands, nearly nine times higher than its three month daily average volume of 537,585 shares.

Just this morning, International Stem Cell Corp., a California-based biotechnology company developing novel stem cell based therapies, announced the completion of the acute toxicity study of the Company's proposed clinical product to treat Parkinson's disease. The recently completed IND-enabling study transplanting rodents with human neural stem cells, derived from ISCO's proprietary parthenogenetic stem cell platform, showed that the cells are well tolerated even at high doses up to the equivalent of 2.2 billion cells in humans. The program continues to progress according to the plan outlined with the FDA at the pre-IND meeting as reported in February 2014. The Company intends to provide a further update early next quarter.

"I'm pleased that we have successfully achieved another important milestone in our Parkinson's disease program. A critical part of the development process, and the preparations for the IND submission, was to establish the highest tolerated dose of our clinical product in rodents," said Dr. Ruslan Semechkin, ISCO's Chief Scientific Officer. "The results of this study show that the doses we will be proposing to the FDA in our phase I clinical study design for the treatment of Parkinson's disease are well below the safety threshold."

ISCO's Parkinson's disease program uses human parthenogenetic neural stem cells (hPNSC), a novel therapeutic cellular product derived from the company's proprietary histocompatible human pluripotent stem cells. hPNSC are self-renewing multipotent cells that are precursors for the major cells of the central nervous system. The ability of hPNSC to (i) differentiate into dopaminergic (DA) neurons and (ii) express neurotrophic factors such as glial derived neurotrophic factor (GDNF) and brain derived neurotrophic factor (BDNF) to protect the nigrostriatal system, offers a new opportunity for the treatment of Parkinson's disease, especially in cases where current small molecule approaches fail to adequately control the symptoms.

ISCO closed the day at $.0972, down 2.9% from its previous close of $.10. is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:

ABOUT US: issues momentum alerts on stocks that can provide gains to day traders. provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the newsletter and receiving alerts from a Pro-Active team of researchers. believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here:

Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.